United States Gene Therapy Market Overview
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 12.20% (2024-2032)
The United States gene therapy market size is experiencing rapid growth, driven by advancements in genetic engineering and increasing patient needs. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 12.20% from 2024 to 2032.
United States Gene Therapy Industry Trends and Drivers:
The United States gene therapy market is driven by significant advancements in genetic research and biotechnology, which have led to the development of innovative therapies targeting a range of genetic disorders and diseases. Over the past decade, breakthroughs in understanding the human genome and the mechanisms of genetic diseases have paved the way for more precise and effective treatments. Techniques such as CRISPR-Cas9, TALENs, and zinc finger nucleases have revolutionized the field by enabling targeted gene editing with high precision. These technological advancements have facilitated the development of therapies that can correct genetic mutations at their source, offering potential cures for previously untreatable conditions. The successful development and approval of gene therapies for diseases like spinal muscular atrophy (SMA) and certain types of inherited blindness underscore the transformative potential of this approach. As a result, there is increasing confidence and investment in the field from both public and private sectors, further accelerating research and development activities.
Another critical factor driving the United States gene therapy market is the growing prevalence of genetic disorders and the unmet medical needs they represent. Genetic disorders, including hemophilia, cystic fibrosis, muscular dystrophy, and various forms of inherited cancers, affect millions of individuals in the United States. Traditional treatment options for these conditions are often limited to managing symptoms rather than addressing the underlying genetic causes. Gene therapy offers a promising alternative by aiming to correct or replace the defective genes responsible for these diseases, thereby providing long-term or potentially permanent solutions. The high burden of genetic disorders on healthcare systems and the quality of life of affected individuals creates a strong demand for innovative treatments, propelling the growth of the gene therapy market. Additionally, the orphan drug status granted to many gene therapies, which provides benefits like market exclusivity and tax incentives, further incentivizes pharmaceutical companies to invest in this area. Regulatory support and the evolving landscape of clinical trials also play a crucial role in driving the gene therapy market in the United States. The U.S. Food and Drug Administration (FDA) has shown a proactive stance in facilitating the development and approval of gene therapies. The agency has established frameworks and guidelines to expedite the approval process for these innovative treatments, recognizing their potential to address significant unmet medical needs. Accelerated approval pathways, breakthrough therapy designations, and priority reviews are some of the regulatory mechanisms in place to support the rapid advancement of gene therapies from research to market.
Moreover, advancements in clinical trial designs, such as adaptive trials and the use of real-world evidence, are improving the efficiency and success rates of gene therapy studies. These regulatory and procedural enhancements reduce the time and cost associated with bringing gene therapies to market, making it a more attractive and feasible endeavor for biotech companies and researchers.
United States Gene Therapy Industry Segmentation:
The report has segmented the market into the following categories:
Gene Type Insights:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide Gene
- Deficiency
- Growth Factors
- Receptors
- Others
Vector Type Insights:
- Viral Vector
- Adenoviruses
- Lentiviruses
- Retroviruses
- Adeno-Associated Virus
- Herpes Simplex Virus
- Poxvirus
- nia ViruVaccis
- Others
- Non-Viral Techniques
- Naked and Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
Delivery Method Insights:
- In-Vivo Gene Therapy
- Ex-Vivo Gene Therapy
Application Insights:
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Others
Regional Insights:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Ask analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=11240&flag=F
Browse more research report:
| United States Radiopharmaceuticals Market |
| United States Gaming Market |
| United States Honey Market |
| United States Led Lighting Market |
| United States Collaborative Robot Market |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145